FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011804589> ?p ?o ?g. }

• W2011804589 endingPage "833" @default.
• W2011804589 startingPage "828" @default.
• W2011804589 abstract "Background Recursive partitioning analysis has shown that Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≥2, male sex, and age ≥70 years are prognostic of poor outcome in locally advanced non-small cell lung cancer (LA-NSCLC) patients. Concurrent chemoradiation therapy (CRT) improves survival, but toxicity is a concern in this frail patient cohort. We therefore opened this trial of concurrent definitive thoracic radiation therapy (XRT) and cetuximab, followed by consolidation docetaxel plus cetuximab. Methods and Materials Eligible patients had pathologically proven, unresectable LA-NSCLC (stage IIA-“dry” IIIB). They had ECOG PS 2 or weight loss ≥5% in 3 months or were aged ≥70 years. The primary objective was progression-free survival (PFS). Secondary objectives included overall survival (OS) and overall response rate (ORR). Results From May 2008 to November 2010, a total of 32 patients were evaluated in our single-institution, institutional review board–approved prospective clinical trial. Three patients were screen failures and 2 more withdrew consent before treatment, leaving 27 evaluable patients. One was removed because of poor therapy compliance, and 2 were taken off trial because of grade 3 cetuximab-related toxicities but were followed up under intent-to-treat analysis. The median follow-up and OS were 10.5 months. The median PFS was 7.5 months. The ORR was 59.3%. Eight early/sudden deaths were reported. Upon review, 6 patients developed severe pulmonary complications. Conclusions Patients enrolled in this trial had improved OS compared with poor-PS historical controls (10.5 vs 6.4 months) and comparable OS to good-PS historical controls (10.5 vs 11.9 months) treated with XRT alone. However, pulmonary toxicity is a concern. Consolidative cetuximab/docetaxel, in conjunction with high-dose radiation therapy, is a putative cause. Recursive partitioning analysis has shown that Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≥2, male sex, and age ≥70 years are prognostic of poor outcome in locally advanced non-small cell lung cancer (LA-NSCLC) patients. Concurrent chemoradiation therapy (CRT) improves survival, but toxicity is a concern in this frail patient cohort. We therefore opened this trial of concurrent definitive thoracic radiation therapy (XRT) and cetuximab, followed by consolidation docetaxel plus cetuximab. Eligible patients had pathologically proven, unresectable LA-NSCLC (stage IIA-“dry” IIIB). They had ECOG PS 2 or weight loss ≥5% in 3 months or were aged ≥70 years. The primary objective was progression-free survival (PFS). Secondary objectives included overall survival (OS) and overall response rate (ORR). From May 2008 to November 2010, a total of 32 patients were evaluated in our single-institution, institutional review board–approved prospective clinical trial. Three patients were screen failures and 2 more withdrew consent before treatment, leaving 27 evaluable patients. One was removed because of poor therapy compliance, and 2 were taken off trial because of grade 3 cetuximab-related toxicities but were followed up under intent-to-treat analysis. The median follow-up and OS were 10.5 months. The median PFS was 7.5 months. The ORR was 59.3%. Eight early/sudden deaths were reported. Upon review, 6 patients developed severe pulmonary complications. Patients enrolled in this trial had improved OS compared with poor-PS historical controls (10.5 vs 6.4 months) and comparable OS to good-PS historical controls (10.5 vs 11.9 months) treated with XRT alone. However, pulmonary toxicity is a concern. Consolidative cetuximab/docetaxel, in conjunction with high-dose radiation therapy, is a putative cause." @default.
• W2011804589 created "2016-06-24" @default.
• W2011804589 creator A5007121755 @default.
• W2011804589 creator A5009314752 @default.
• W2011804589 creator A5014436324 @default.
• W2011804589 creator A5022912407 @default.
• W2011804589 creator A5044430435 @default.
• W2011804589 creator A5046273815 @default.
• W2011804589 creator A5055888843 @default.
• W2011804589 creator A5058514584 @default.
• W2011804589 creator A5062655853 @default.
• W2011804589 creator A5064494204 @default.
• W2011804589 creator A5064716632 @default.
• W2011804589 creator A5073487553 @default.
• W2011804589 creator A5080538468 @default.
• W2011804589 creator A5090807936 @default.
• W2011804589 date "2014-11-01" @default.
• W2011804589 modified "2023-09-27" @default.
• W2011804589 title "Phase 2 Study of Concurrent Cetuximab Plus Definitive Thoracic Radiation Therapy Followed by Consolidation Docetaxel Plus Cetuximab in Poor Prognosis or Elderly Patients With Locally Advanced Non-Small Cell Lung Cancer" @default.
• W2011804589 cites W1912918175 @default.
• W2011804589 cites W1944220675 @default.
• W2011804589 cites W1967974729 @default.
• W2011804589 cites W1971564125 @default.
• W2011804589 cites W2008928830 @default.
• W2011804589 cites W2014477874 @default.
• W2011804589 cites W2014725195 @default.
• W2011804589 cites W2018713883 @default.
• W2011804589 cites W2019926572 @default.
• W2011804589 cites W2041457158 @default.
• W2011804589 cites W2046225622 @default.
• W2011804589 cites W2076880391 @default.
• W2011804589 cites W2105024669 @default.
• W2011804589 cites W2105969273 @default.
• W2011804589 cites W2122999279 @default.
• W2011804589 cites W2124290051 @default.
• W2011804589 cites W2128529067 @default.
• W2011804589 cites W2129586472 @default.
• W2011804589 cites W2139248078 @default.
• W2011804589 cites W2140469315 @default.
• W2011804589 cites W2152939220 @default.
• W2011804589 cites W2155053061 @default.
• W2011804589 cites W2155384808 @default.
• W2011804589 cites W2163709153 @default.
• W2011804589 cites W2229509524 @default.
• W2011804589 cites W2264904051 @default.
• W2011804589 cites W4250329983 @default.
• W2011804589 doi "https://doi.org/10.1016/j.ijrobp.2014.07.023" @default.
• W2011804589 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25216856" @default.
• W2011804589 hasPublicationYear "2014" @default.
• W2011804589 type Work @default.
• W2011804589 sameAs 2011804589 @default.
• W2011804589 citedByCount "10" @default.
• W2011804589 countsByYear W20118045892015 @default.
• W2011804589 countsByYear W20118045892017 @default.
• W2011804589 countsByYear W20118045892019 @default.
• W2011804589 countsByYear W20118045892021 @default.
• W2011804589 countsByYear W20118045892022 @default.
• W2011804589 countsByYear W20118045892023 @default.
• W2011804589 crossrefType "journal-article" @default.
• W2011804589 hasAuthorship W2011804589A5007121755 @default.
• W2011804589 hasAuthorship W2011804589A5009314752 @default.
• W2011804589 hasAuthorship W2011804589A5014436324 @default.
• W2011804589 hasAuthorship W2011804589A5022912407 @default.
• W2011804589 hasAuthorship W2011804589A5044430435 @default.
• W2011804589 hasAuthorship W2011804589A5046273815 @default.
• W2011804589 hasAuthorship W2011804589A5055888843 @default.
• W2011804589 hasAuthorship W2011804589A5058514584 @default.
• W2011804589 hasAuthorship W2011804589A5062655853 @default.
• W2011804589 hasAuthorship W2011804589A5064494204 @default.
• W2011804589 hasAuthorship W2011804589A5064716632 @default.
• W2011804589 hasAuthorship W2011804589A5073487553 @default.
• W2011804589 hasAuthorship W2011804589A5080538468 @default.
• W2011804589 hasAuthorship W2011804589A5090807936 @default.
• W2011804589 hasConcept C121608353 @default.
• W2011804589 hasConcept C126322002 @default.
• W2011804589 hasConcept C141071460 @default.
• W2011804589 hasConcept C143998085 @default.
• W2011804589 hasConcept C2776256026 @default.
• W2011804589 hasConcept C2776694085 @default.
• W2011804589 hasConcept C2776907518 @default.
• W2011804589 hasConcept C2779998722 @default.
• W2011804589 hasConcept C2780739268 @default.
• W2011804589 hasConcept C2781190966 @default.
• W2011804589 hasConcept C509974204 @default.
• W2011804589 hasConcept C526805850 @default.
• W2011804589 hasConcept C535046627 @default.
• W2011804589 hasConcept C71924100 @default.
• W2011804589 hasConceptScore W2011804589C121608353 @default.
• W2011804589 hasConceptScore W2011804589C126322002 @default.
• W2011804589 hasConceptScore W2011804589C141071460 @default.
• W2011804589 hasConceptScore W2011804589C143998085 @default.
• W2011804589 hasConceptScore W2011804589C2776256026 @default.
• W2011804589 hasConceptScore W2011804589C2776694085 @default.
• W2011804589 hasConceptScore W2011804589C2776907518 @default.
• W2011804589 hasConceptScore W2011804589C2779998722 @default.
• W2011804589 hasConceptScore W2011804589C2780739268 @default.
• W2011804589 hasConceptScore W2011804589C2781190966 @default.
• W2011804589 hasConceptScore W2011804589C509974204 @default.

• next